ArticleInternational journal of chronic obstructive pulmonary disease2023
Association of Blood Inflammatory Biomarkers with Clinical Outcomes in Patients with AECOPD: An 8-Year Retrospective Study in Beijing.
Article in International journal of chronic obstructive pulmonary disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Predictive value of neutrophil-lymphocyte ratio for all-cause mortality in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.BMC pulmonary medicine · 2025Pooled it
- Article
- Stage-Dependent Reorganization of Inflammatory Biomarker Networks During Acute Exacerbations of COPD.Life (Basel, Switzerland) · 2026Article
- Association between the Dietary Inflammatory Index and lung function in exacerbated chronic obstructive pulmonary disease: The mediating role of inflammatory indicators.Asia Pacific journal of clinical nutrition · 2026Article
- Association Between Cardiovascular Comorbidities and Clinical Outcomes in Patients Hospitalized for AECOPD.International journal of chronic obstructive pulmonary disease · 2026Article
- Multimodal machine learning predicts type 2 respiratory failure in COPD exacerbations: a multicenter XGBoost model with clinical nomogram.Frontiers in medicine · 2026Article
- Association of Peak Expiratory Flow with Pulmonary Fungal Infection in Hospitalized Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Single-Center Retrospective Study.International journal of chronic obstructive pulmonary disease · 2026Article
- Predictive value of admission levels of IL-6 and PCT combined with the peri-treatment change in NLR (ΔNLR) for hospital length of stay in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD).American journal of translational research · 2026Article
- Mortality Predictors in Patients with Severe COPD Exacerbation.Journal of clinical medicine · 2025Article
- Construction and evaluation of a 180-day readmission prediction model for chronic heart failure patients based on sCD40L.Medicine · 2025Article
- Development and validation of the machine learning model for acute exacerbation of chronic obstructive pulmonary disease prediction based on inflammatory biomarkers.Frontiers in medicine · 2025Article
- Effects of graded exercise rehabilitation on inflammatory factors and T-lymphocyte subsets in patients with acute exacerbation of chronic obstructive pulmonary disease: a randomized controlled trial.Frontiers in medicine · 2025Article
- Blood Eosinophil Stability Predicts Clinical Outcomes in Hospitalized Patients with Acute Exacerbations of COPD.International journal of chronic obstructive pulmonary disease · 2025Article
- Higher blood manganese level associated with increased risk of adult latent tuberculosis infection in the US population.Frontiers in public health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To discover potential inflammatory biomarkers, which can compare favorably with traditional biomarkers, and their best cut-offs at first admission to predict clinical outcomes (short-term and long-term) and the risk of readmission among acute exacerbations of chronic obstructive pulmonary disease (AECOPD) patients. Patients and Methods: Novel inflammatory biomarkers (such as the neutrophil-lymphocyte ratio [NLR], platelet-lymphocyte ratio [PLR], etc.) were compared with traditional biomarkers by Pearson's correlation test. Logistic regression analysis and receiver operating characteristic (ROC) curves were applied to judge the accuracy of these novel biomarkers to predict in-hospital mortality. Results: Surviving AECOPD patients had lower NLR, PLR, and lymphocyte-to-monocyte ratios than non-survival patients (all P < 0.001). According to Pearson's correlation test, there was a linear correlation between novel and traditional biomarkers (all P < 0.05). In terms of a single biomarker, the AUC value of NLR was the largest, which was not inferior to C-reactive protein (Z-P = 0.064), and superior to erythrocyte sedimentation rate (Z-P = 0.002) and other novel single inflammatory biomarkers (all Z-P < 0.05). The mortality of patients with NLR ≥ 4.43 was 2.308-fold higher than that of patients with NLR < 4.43. After dividing patients into a higher or lower NLR group, pooled results showed that patients with NLR ≥ 4.43 had a higher rate of treatment failure, intensive care unit admission, longer hospital length of stay, one-year mortality after the index hospitalization, and overall mortality than patients with NLR < 4.43 (all P < 0.001). Patients with NLR ≥ 4.43 were associated with higher and earlier first readmission due to AECOPD than patients with lower NLR. Conclusion: NLR was the best to forecast the clinical prognosis and readmission risk among AECOPD patients, which was not inferior to CRP, and the best cut-off value of NLR was 4.43.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.